FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:1272-1276 May 3, 1990 Number 18 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We studied the efficacy and safety of oral tetrahydroaminoacridine (THA) combined with lecithin in 52 patients with Alzheimer's disease. The maximal tolerated dose of THA (up to 100 mg per day) was determined during an eight-week titration period, after which the tolerated dose of THA or placebo was given during two sequential randomized periods of treatment lasting eight weeks each. Highly purified lecithin (4.7 g per day) was administered during all phases of the study. Efficacy was expressed in terms of scores on the Mini-Mental State (MMS) test, the modified MMS test, the Hierarchic Dementia Scale, the Rapid Disability Rating Scale-II, and the behavioral scale of Reisberg et al. Safety was assessed by careful clinical monitoring as well as serial measurements of liver aminotransferases. Forty-six patients completed the titration period, and 39 completed the double-blind period, during which only the MMS score showed a small but significant increase (P less than 0.05) after four weeks of treatment with THA. Autonomic side effects of THA were common but mild. Reversible elevations of serum aspartate and alanine aminotransferase levels to three or more times the upper limit of normal occurred in 17 percent of patients; most of the patients affected were women. A liver biopsy performed in one patient showed resolving focal liver-cell necrosis. These studies fail to demonstrate a significant clinical benefit of THA given orally in a maximal dose of 100 mg per day over a period of eight weeks in combination with lecithin.

Source Information

McGill Centre for Studies in Aging, McGill University, Montreal, PQ, Canada.

This article has been cited by other articles:

• Chow, T. W., MacLean, C. H. (2001). Quality Indicators for Dementia in Vulnerable Community-Dwelling and Hospitalized Elders. ANN INTERN MED 135: 668-676 [Full Text]  
• Doody, R. S., Stevens, J.C., Beck, C., Dubinsky, R.M., Kaye, J.A., Gwyther, L., Mohs, R.C., Thal, L.J., Whitehouse, P.J., DeKosky, S.T., Cummings, J.L. (2001). Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154-1166 [Abstract] [Full Text]  
• Farlow, M. R., Hake, A., Messina, J., Hartman, R., Veach, J., Anand, R. (2001). Response of Patients With Alzheimer Disease to Rivastigmine Treatment Is Predicted by the Rate of Disease Progression. Arch Neurol 58: 417-422 [Abstract] [Full Text]  
• Qizilbash, N., Whitehead, A., Higgins, J., Wilcock, G., Schneider, L., Farlow, M., for the Dementia Trialists' Collaboration, (1998). Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials. JAMA 280: 1777-1782 [Abstract] [Full Text]  
• Eccles, M., Clarke, J., Livingston, M., Freemantle, N., Mason, J. (1998). North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ 317: 802-808 [Full Text]  
• Gold, D. P., Dastoor, D., Zieren, C. (1996). Further validation of the Hierarchic Dementia Scale: A longitudinal study of cognitive function in dementia. AM J ALZHEIMERS DIS OTHER DEMEN 11: 2-6 [Abstract]  
• Prentice, N., Van Beck, M., Dougall, N. J., Moffoot, A. P. R., O'Carroll, R. E., Goodwin, G. M., Ebmeier, K. P. (1996). A double-blind, placebo-controlled study of tacrine in patients with Alzheimer's disease using SPET. J Psychopharmacol 10: 175-181 [Abstract]  
• Patel, S. V. (1995). Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review. J Geriatr Psychiatry Neurol 8: 81-95 [Abstract]  
• Allen, N.H.P., Burns, A. (1995). The treatment of Alzheimer's disease. J Psychopharmacol 9: 43-56  
• Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., Gracon, S. I., the Tacrine Study Group, , Apter, J. T., Lazarus, C. N., Baker, K. E., Barnett, M., Baumel, B., Eisner, L. S., Bennett, D., Forchetti, C., Levin, A., Blass, J. P., Nolan, K. A., Gaines, E. R., Relkin, N., Borison, R. L., Diamond, B., Celesia, G. G., Ross, A. P., Dexter, J., Doody, R., Lipscomb, L., Kreiter, K., DuBoff, E. A., Block, P., Marshall, D., Westergaard, N., Earl, N. L., Vann Wyne, S., Hinman-Smith, E., Farlow, M., Hendrie, H. C., Caress, J. A., Farmer, M., Harper, J. E., Ferguson, J., Foster, N. L., Barbas, N. R., Bluemlein, L. A., Gelb, D. J., Berent, S., Giordani, B., Greenwald, M., Bergman, S., Roger, L. F., Groenendyk, A., Wood, M., Jurkowski, C., Katz, I., Doyle, S., Smith, B. D., Kellner, C., Bernstein, H. J., Bachman, D. L., Knopman, D. S., Deinard, S., Langley, L., Bridges, S., Margolin, R. A., Burger, M. C., Wiser, S. L., Crenshaw, C., Morris, J. C., Rubin, E. H., Coats, M. A., Reyes, P. F., Bentz, C., Doyle, L. L., Rymer, M. M., Bettinger, I. E., Laubinger, M. P., Sadowsky, C. H., Martinez, W., Zuniga, J., Stone, R., Winner, P., Mate, L., Lessard, C., Schneider, L., Pawluczyk, S., Smith, W. T., Losk, S. N., Marambe, L., Solomon, P. R., Pendlebury, W. W., Groccia-Ellison, M. E., Edwards, K. R., Taylor, J., Calabrese, V. P., Harkins, S. W., Thein, S. G. Jr, Dewar, J. A., Williams, G., Drennan, C., Tuttle, P., Principi, N., Ford, E. M., Tyndall, R. J., Kelley, C. K. (1994). A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease. JAMA 271: 985-991 [Abstract]  
• Watkins, P. B., Zimmerman, H. J., Knapp, M. J., Gracon, S. I., Lewis, K. W. (1994). Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease. JAMA 271: 992-998 [Abstract]  
• Maltby, N, Broe, G A, Creasey, H, Jorm, A F, Christensen, H, Brooks, W S (1994). Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. BMJ 308: 879-883 [Abstract] [Full Text]  
• Crum, R. M., Anthony, J. C., Bassett, S. S., Folstein, M. F. (1993). Population-Based Norms for the Mini-Mental State Examination by Age and Educational Level. JAMA 269: 2386-2391 [Abstract]  
• Farlow, M., Gracon, S. I., Hershey, L. A., Lewis, K. W., Sadowsky, C. H., Dolan-Ureno, J., the Tacrine Study Group, , Asher, S. W., Beaver, C., Hamilton, D., Bergman, S. M., Roger, L. F., Black, S. E., Carr, S., Winchester, T., Layne, E., Clark, C., Dexter, J., DuBoff, E. A., Farlow, M., Hendrie, H., Caress, J., Shatz, R., Hanna, G. R., Brashear, H. R., Damgaard, P., Hershey, L. A., Donnelly, K., Burch, K., Homan, R. W., McSweeney, A. J., Ann Barczak, M., Mattes, J. A., Hermann, A. M., Mohr, E., Mendis, T., Roberts, J., Begin, L., Sampson, M., Ott, B. R., Lannon, M. C., Prendergast, J. J., Madan, S., Hanning, R., Sadowsky, C. H., Martinez, W., Stone, R., Winner, P., Zuniga, J., Mate, L. J., Ehlert, B. J., Lessard, C., Seltzer, B., Taylor, J. R., Calabrese, V. P., Harkins, S. W., Weis, S. J., Slade, W., Sommer, B. R., Wichter, M., Schwartz, M., Eastman, J., Thein, S. G. Jr, Williams, G., Dewar, J. A., Foster, N. L., Bluemlein, L. A., Gelb, D. J., Berent, S., Giordani, B., Baron, B. A., Myers, S. (1992). A Controlled Trial of Tacrine in Alzheimer's Disease. JAMA 268: 2523-2529 [Abstract]  
• Small, G. W. (1992). Tacrine for Treating Alzheimer's Disease. JAMA 268: 2564-2565 [Abstract]  
• Sano, M., Bell, K., Cote, L., Dooneief, G., Lawton, A., Legler, L., Marder, K., Naini, A., Stern, Y., Mayeux, R. (1992). Double-blind Parallel Design Pilot Study of Acetyl Levocarnitine in Patients With Alzheimer's Disease. Arch Neurol 49: 1137-1141 [Abstract]  
• Perryman, K. M., Fitten, L. J. (1991). Quantitative EEG During a Double-Blind Trial of THA and Lecithin in Patients with Alzheimer's Disease. J Geriatr Psychiatry Neurol 4: 127-133 [Abstract]  
• Cooper, J. K. (1991). Drug Treatment of Alzheimer's Disease. Arch Intern Med 151: 245-249 [Abstract]  
• Sahgal, A., Keith, A.B., Lloyd, S. (1990). Effects of nicotine, oxotremorine and 9-amino 1,2,3,4- tetrahydroacridine (tacrine) on matching and non matching to position in rats: no evidence for mnemonic enhancement. J Psychopharmacol 4: 210-218 [Abstract]